About us > Dr Patrick Bowden

Dr Patrick Bowden

MBBS, FRANZCR

Radiation Oncologist

Dr Patrick Bowden is committed to providing comprehensive, patient-centred cancer care. He is a highly experienced doctor who remains at the forefront of cutting-edge radiation therapy techniques and clinical research.

Quick Scroll

Clinical Expertise

Dr Patrick Bowden accepts referrals for all cancer types and for non-malignant conditions

with a special clinical interest in:

Precision Cancer Care

Enquire Today

Precision Joint Care

Free Suitability Check

Dr Patrick Bowden

Biography

Dr Patrick Bowden is committed to providing comprehensive, patient-centred cancer care. He is a highly experienced doctor who remains at the forefront of cutting-edge radiation therapy techniques and clinical research.

With over 20 years of experience as a radiation oncologist, Dr Patrick Bowden is a leading expert in the field of advanced radiation therapy. He obtained his medical degree from the University of Melbourne in 1994. His oncology career began at the prestigious Peter MacCallum Cancer Centre, where he became Director of the Tattersall's Cancer Centre. Dr Bowden has been instrumental in building some of the nation's most advanced radiotherapy services, including his role as the inaugural Director of Epworth Radiation Oncology, where he established Australia's largest stereotactic radiation therapy service. He is one of the most experienced stereotactic radiotherapy doctors in Australia, having delivered over 2000 courses of treatment in his career.

He provides stereotactic treatment at a number of cancer centres throughout Melbourne, and also in Canberra. Many patients travel from other parts of Australia and Asia to have treatment with him, and accommodation is made available to them.

Dr Bowden's expertise is not just clinical but also academic. He has been the principal investigator in numerous groundbreaking clinical trials, including the TRANSFORM study, which evaluated the efficacy of stereotactic radiation therapy for oligometastatic prostate cancer. This was the largest trial ever conducted in the world on this disease. His work continues to shape the future of radiation oncology, with a focus on improving patient outcomes and advancing cancer care.

Furthermore, his experience as a clinician and researcher, as well as expertise as a Director of Cancer Centres, has been recognised by major hospitals in Melbourne, who have elected him to their Medical Advisory Committees since 2007.

Research

Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?

Khanna Y, Chinni V, Gnanasambantham K, Paul E, O'Sullivan R, Ballok ZE, Ryan A, Ramdave S, Sivaratnam D, Bowden P, Guerrieri M, Ranasinghe WKB, Frydenberg M.

BJU Int. 2026 Apr;137(4):619-628.

Stereotactic body radiotherapy for lung oligometastatic prostate cancer: An international retrospective multicenter study.

Rogé M, Bowden P, Conway P, Franzese C, Scorsetti M, Seront E, Blanchard P, Terlizzi M, Khalifa J, Pasquier C, Shick U, Siva S, Paul J, Supiot S.

Clin Transl Radiat Oncol. 2025 Mar 10;52:100944.

Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial

See AW, Conway P, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Pranavan G, Peters J, Smyth LML, Gwini SM, McKenzie DP, Bowden P.

Int J Cancer. 2024 Oct 1;155(7):1248-1256.

Can 68 Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?

Khanna Y, Chinni V, Gnanasambantham K, O'Sullivan R, Ballok ZE, Ryan A, Ramdave S, Sivaratnam D, Bowden P, Guerrieri M, Ranasinghe WKB, Frydenberg M.

BJU Int. 2023 Sep;132(3):321-328.

Distant Nodes Seen on PSMA PET-CT Staging Predicts Post-Treatment Progression in Men with Newly Diagnosed Prostate Cancer-A Prospective Cohort Study.

Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, Murphy D, Sengupta S, Bowden P, Lawrentschuk N

Cancers (Basel). 2022 Dec 13;14(24):6134.

Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a peri-rectal hydrogel spacer: 3-year outcomes from a phase II trial.

See AW, Bowden P, Wells G, Appu S, Lawrentschuk N, Liodakis P, Pandeli C, Aarons Y, Smyth LML, McKenzie DP.

Radiat Oncol. 2022 Jul 25;17(1):131.

PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up.

Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, Murphy D, Sengupta S, Bowden P, Lawrentschuk N.

Cancers (Basel). 2022 May 31;14(11):2717.

68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial.

Bowden P, See AW, So K, Lawrentschuk N, Moon D, Murphy DG, Rao R, Crosthwaite A, King D, Haxhimolla H, Grummet J, Ruljancich P, Gyomber D, Landau A, Campbell N, Frydenberg M, Smyth LML, Nolan S, Gwini SM, McKenzie DP.

World J Urol. 2021 Nov;39(11):4117-4125.

Use of prostate-specific membrane antigen positron-emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer.

Anton A, Kamel Hasan O, Ballok Z, Bowden P, Costello AJ, Harewood L, Corcoran NM, Dundee P, Peters JS, Lawrentschuk N, Troy A, Webb D, Chan Y, See A, Siva S, Murphy D, Hofman MS, Tran B.

BJU Int. 2020 Oct;126(4):433-435.

Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial.

Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Crosthwaite A, Pranavan G, Peters JS, So K, Gwini SM, McKenzie DP, Nolan S, Smyth LML, Everitt C.

Int J Cancer. 2020 Jan 1;146(1):161-168.

Endobronchial Prostate Metastasis.

Bonney A, Bowden P, Antippa P, Steinfort D.

J Bronchology Interv Pulmonol. 2017 Jan;24(1):e1-e3.

Stereotactic radiosurgery for brain and spine metastases.

Bowden P, See AW, Dally MJ, Bittar RG.

J Clin Neurosci. 2014 May;21(5):731-4.

When you're ready, we're
here to listen and help.

Precision Cancer Care

Enquire Today

Precision Joint Care

Free Suitability Check